Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HTL0022562

            Therapeutic Area: Neurology Product Name: HTL0022562

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals

            Deal Size: $380.0 million Upfront Cash: $10.0 million

            Deal Type: Collaboration December 01, 2020


            Biohaven will get exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders. The portfolio includes the lead candidate HTL0022562.